Stevens Capital Management LP Acquires Shares of 81,886 Pfizer Inc. (NYSE:PFE)

Key Points

• Stevens Capital Management LP has invested approximately $2.08 million in Pfizer Inc. by acquiring 81,886 shares in the first quarter.
• Pfizer reported an EPS of $0.92 for its latest quarter, surpassing analysts' estimates but showing a 7.8% decline in revenue year-over-year.
• The biopharmaceutical company recently declared a quarterly dividend of $0.43 per share, representing an annualized yield of 6.78% and a payout ratio of 124.64%.

Stevens Capital Management LP acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 81,886 shares of the biopharmaceutical company's stock, valued at approximately $2,075,000.

A number of other hedge funds have also bought and sold shares of PFE. Pacer Advisors Inc. grew its position in Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Cetera Investment Advisers grew its position in shares of Pfizer by 15.5% during the 1st quarter. Cetera Investment Advisers now owns 2,335,151 shares of the biopharmaceutical company's stock worth $59,173,000 after buying an additional 313,587 shares in the last quarter. Avantax Advisory Services Inc. grew its holdings in Pfizer by 5.9% during the 1st quarter. Avantax Advisory Services Inc. now owns 369,411 shares of the biopharmaceutical company's stock worth $9,361,000 after acquiring an additional 20,421 shares in the last quarter. Hamilton Point Investment Advisors LLC grew its holdings in Pfizer by 18.5% during the 1st quarter. Hamilton Point Investment Advisors LLC now owns 175,596 shares of the biopharmaceutical company's stock worth $4,450,000 after acquiring an additional 27,431 shares in the last quarter. Finally, Brookwood Investment Group LLC bought a new position in shares of Pfizer during the first quarter valued at approximately $227,000. Institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PFE. Bank of America increased their target price on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Citigroup raised their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Redburn Atlantic lowered their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research report on Wednesday, April 30th. Finally, Morgan Stanley raised their price objective on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus price target of $28.55.

Pfizer Price Performance

Shares of PFE stock traded down $0.57 during trading hours on Friday, hitting $24.79. 35,628,980 shares of the company's stock were exchanged, compared to its average volume of 38,205,096. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm has a market cap of $140.91 billion, a P/E ratio of 17.96, a P/E/G ratio of 0.92 and a beta of 0.58. The firm has a 50 day moving average of $24.30 and a two-hundred day moving average of $24.68. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The company's revenue for the quarter was down 7.8% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.94%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.